Oncology · Precision Cancer Testing
MyeloMap
52-gene Myeloid Malignancy Panel
Targeted genomic profiling for AML, MDS and related myeloid neoplasms.
Peripheral blood/Bone marrow
Sample Type
1 FFPE block or 10–15 slides
Samples
10–14 working days
Turnaround Time
About the Test
MyeloMap at Nucleome Informatics
52-gene Myeloid Malignancy Panel
Why this Test Matters
Precision oncology depends on identifying clinically actionable genomic alterations. This assay helps clinicians select targeted therapies, evaluate immunotherapy eligibility, identify prognostic biomarkers, detect resistance mechanisms, and match patients to suitable clinical trials while minimizing sequential testing.
Who Should Consider this Test
- AML
- MDS
- Disease progression
- Relapse
Applicable Cancer Types
AML, MDS, Myeloid neoplasms
Test Details
What the test covers and delivers
What is Covered
- 52 genes
- SNVs
- InDels
- Risk biomarkers
Clinical Utility
- Treatment selection
- Prognostic and predictive biomarkers
- Clinical trial matching
- Identification of actionable alterations
- Comprehensive clinical interpretation
Technology
Targeted myeloid sequencing
Key Features
Test specifications
| Parameter | Details |
|---|---|
| Sample Type | Peripheral blood/Bone marrow |
| Samples | 1 FFPE block or 10–15 slides |
| Turnaround Time | 10–14 working days |
| Report Includes | Variant interpretation, therapy associations, clinically actionable biomarkers |
| Quality | High-depth NGS with rigorous QC |
Talk to our team. Email info@nucleomeinfo.com or call +91 40 40114169 to discuss sample requirements and turnaround for MyeloMap.









